PHILADELPHIA (PRWEB) September 27, 2019 -- ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has been named the Health IT Innovator of the Year by the Pittsburgh Technology Council.
ERT has been recognized for its suite of innovative clinical trial solutions that pharmaceutical researchers rely on to determine the safety and effectiveness of new medical treatments. The award was presented on September 25 during the annual Tech 50 Gala.
The Tech 50 Awards program recognizes the companies that are impacting their customers and driving the success of the Pittsburgh region ─ and the industry at large ─ through innovative ideas and state-of-the-art technologies.
ERT’s electronic Clinical Outcome Assessment (eCOA), Cardiac Safety, Respiratory, Imaging, Real World Evidence and Trial Oversight solutions improve clinical trial efficiencies, overcome the limitations of traditional paper-driven approaches, and deliver the highest quality patient data so it’s biopharmaceutical customers can accelerate clinical development, getting novel treatments to patients sooner. ERT’s eClinical solutions have been used in the development of more than half of all drugs approved by the FDA since 2013.
“We’re very honored and grateful to the Tech 50 judging panel for identifying ERT among a crowded field of innovative companies in the Pittsburgh region,” said Jim Corrigan, President and CEO, ERT. “This award really represents the hard work our employees do every day – in Pittsburgh, and around the globe ─ and their commitment to delivering the solutions and services our customers rely on as they develop new medical treatments for patients worldwide.”
For more information on ERT’s suite of eClinical solutions, visit ert.com
About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.
For more information, go to ert.com or follow us on LinkedIn and Twitter.
Christine Tobin, ERT, http://www.ert.com, +1 4127194568, [email protected]
Share this article